Results · Apr-Jun 2026
Epigral Q1 FY27 results
Sales grew 16% to ₹705 crore from ₹607 crore in Apr-Jun 2025.
Operating profit grew 10% to ₹179 crore, an operating margin of 25.4% (down 1.5 points from a year ago).
Net profit fell 38% to ₹99.7 crore from ₹161 crore in Apr-Jun 2025.
Against Jan-Mar 2026: sales −4%, net profit +23%.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 705.4 | 606.5 | +16% |
| Operating profit (EBITDA) | 179.2 | 163.4 | +10% |
| Operating margin | 25.4% | 26.9% | −1.5 pts |
| Net profit | 99.7 | 160.7 | −38% |
Consolidated figures. Margins & ratios change in percentage points (pts).
The last 7 quarters
From the company's results filed on BSE (Consolidated). Business numbers only. Education & analysis, not investment advice or a recommendation.